Skip to content

Study · Randomized controlled trial · 2012

17 results

Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial.

Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M

Diabetes care30 Jul 2012Cited by 52 (Europe PMC)

PMID22851600 (opens in a new tab)PMCIDPMC3447855 (opens in a new tab)DOI10.2337/dc11-2113 (opens in a new tab)PepBankPUB-22851600
Read at sourcePubMedAsk about this study
Jump to 17 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study17

17 results from studies that gave the peptide. 17 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, switching from sitagliptin to liraglutide 1.2 mg/day lowered HbA1c by a further 0.2%.

    In plain wordsIn adults with type 2 diabetes, switching from sitagliptin to liraglutide 1.2 mg lowered HbA1c a little more.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change after switch, liraglutide 1.2 mg
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg/day · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change after switch
    −0.2%
    liraglutide 1.2 mg/day

    Source sentences

    Summary
    Although 52 weeks of sitagliptin changed glycosylated hemoglobin (HbA(1c)) by -0.9% from baseline, additional decreases occurred after switching to liraglutide (1.2 mg/day, -0.2%, P = 0.006; 1.8 mg/day, -0.5%, P = 0.0001).
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, switching from sitagliptin to liraglutide 1.8 mg/day lowered HbA1c by a further 0.5%.

    In plain wordsIn adults with type 2 diabetes, switching from sitagliptin to liraglutide 1.8 mg lowered HbA1c more.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change after switch, liraglutide 1.8 mg
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change after switch
    −0.5%
    liraglutide 1.8 mg/day

    Source sentences

    Summary
    Although 52 weeks of sitagliptin changed glycosylated hemoglobin (HbA(1c)) by -0.9% from baseline, additional decreases occurred after switching to liraglutide (1.2 mg/day, -0.2%, P = 0.006; 1.8 mg/day, -0.5%, P = 0.0001).
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, switching from sitagliptin to liraglutide 1.2 mg/day reduced fasting plasma glucose by 0.8 mmol/L.

    In plain wordsIn adults with type 2 diabetes, switching to liraglutide 1.2 mg lowered fasting blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose change after switch, liraglutide 1.2 mg
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg/day · 26 weeksAs given in this study (human).

    Measurements

    FPG change
    −0.8 mmol/L
    liraglutide 1.2 mg/day

    Source sentences

    Summary
    Conversion to liraglutide was associated with reductions in fasting plasma glucose (FPG) (1.2 mg/day, -0.8 mmol/L, P = 0.0004; 1.8 mg/day, -1.4 mmol/L, P < 0.0001) and body weight (1.2 mg/day, -1.6 kg; 1.8 mg/day, -2.5 kg; both P < 0.0001) and with an increased proportion of patients reaching HbA(1c…
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, switching from sitagliptin to liraglutide 1.8 mg/day reduced fasting plasma glucose by 1.4 mmol/L.

    In plain wordsIn adults with type 2 diabetes, switching to liraglutide 1.8 mg lowered fasting blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose change after switch, liraglutide 1.8 mg
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    FPG change
    −1.4 mmol/L
    liraglutide 1.8 mg/day

    Source sentences

    Summary
    Conversion to liraglutide was associated with reductions in fasting plasma glucose (FPG) (1.2 mg/day, -0.8 mmol/L, P = 0.0004; 1.8 mg/day, -1.4 mmol/L, P < 0.0001) and body weight (1.2 mg/day, -1.6 kg; 1.8 mg/day, -2.5 kg; both P < 0.0001) and with an increased proportion of patients reaching HbA(1c…
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, switching from sitagliptin to liraglutide 1.2 mg/day reduced body weight by 1.6 kg.

    In plain wordsIn adults with type 2 diabetes, switching to liraglutide 1.2 mg lowered body weight by about 1.6 kg.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change after switch, liraglutide 1.2 mg
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Body weight change
    −1.6 kg
    liraglutide 1.2 mg/day

    Source sentences

    Summary
    Conversion to liraglutide was associated with reductions in fasting plasma glucose (FPG) (1.2 mg/day, -0.8 mmol/L, P = 0.0004; 1.8 mg/day, -1.4 mmol/L, P < 0.0001) and body weight (1.2 mg/day, -1.6 kg; 1.8 mg/day, -2.5 kg; both P < 0.0001) and with an increased proportion of patients reaching HbA(1c…
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, switching from sitagliptin to liraglutide 1.8 mg/day reduced body weight by 2.5 kg.

    In plain wordsIn adults with type 2 diabetes, switching to liraglutide 1.8 mg lowered body weight by about 2.5 kg.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change after switch, liraglutide 1.8 mg
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Body weight change
    −2.5 kg
    liraglutide 1.8 mg/day

    Source sentences

    Summary
    Conversion to liraglutide was associated with reductions in fasting plasma glucose (FPG) (1.2 mg/day, -0.8 mmol/L, P = 0.0004; 1.8 mg/day, -1.4 mmol/L, P < 0.0001) and body weight (1.2 mg/day, -1.6 kg; 1.8 mg/day, -2.5 kg; both P < 0.0001) and with an increased proportion of patients reaching HbA(1c…
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the proportion reaching HbA1c below 7% rose from about 30% to about 50% after switching to liraglutide.

    In plain wordsIn adults with type 2 diabetes, more people reached the HbA1c target after switching from sitagliptin to liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion reaching HbA1c <7% after switch
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Proportion HbA1c <7%
    30%
    before switch
    Proportion HbA1c <7%
    50%
    after switch

    Source sentences

    Summary
    with an increased proportion of patients reaching HbA(1c) <7% (from ∼30% to ∼50%).
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, treatment satisfaction improved after switching to liraglutide (pooled 1.2 and 1.8 mg/day, 1.3).

    In plain wordsIn adults with type 2 diabetes, people were more satisfied with treatment after switching to liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseTreatment satisfaction (DTSQ) after switch
    Study

    n: not reported in source

    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    DTSQ change
    1.3 points
    pooled liraglutide 1.2 and 1.8 mg/day

    Source sentences

    Summary
    Overall treatment satisfaction, assessed by the Diabetes Treatment Satisfaction Questionnaire, improved after switching to liraglutide (pooled 1.2 and 1.8 mg/day, 1.3; P = 0.0189).
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  9. 09HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, mostly transient nausea occurred in 21% of participants after switching to liraglutide.

    In plain wordsIn adults with type 2 diabetes, about one fifth of people had nausea, mostly short-lived, after switching to liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea after switch
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Nausea incidence
    21%
    after switch

    Source sentences

    Summary
    After switching, mostly transient nausea occurred in 21% of participants
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  10. 10HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, minor hypoglycemia remained low, in 3-4% of participants, after switching to liraglutide.

    In plain wordsIn adults with type 2 diabetes, few people (3-4%) had mild low blood sugar after switching to liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableMinor hypoglycemia after switch
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.2 or 1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Minor hypoglycemia incidence
    3 to 4%
    after switch

    Source sentences

    Summary
    minor hypoglycemia remained low (3-4% of participants).
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, continuing liraglutide 1.2 mg/day for 78 weeks reduced HbA1c by 0.9% from a baseline of 8.3%.

    In plain wordsIn adults with type 2 diabetes, 78 weeks of liraglutide 1.2 mg lowered HbA1c by 0.9%.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change over 78 weeks, liraglutide 1.2 mg
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg/day · 78 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.9%
    liraglutide 1.2 mg/day, 78 weeks

    Source sentences

    Summary
    Continuing liraglutide treatment at 1.2 mg/day and 1.8 mg/day for 78 weeks reduced HbA(1c) (baseline 8.3 and 8.4%, respectively) by -0.9 and -1.3%, respectively; FPG by -1.3 and -1.7 mmol/L, respectively; and weight by -2.6 and -3.1 kg, respectively, with 9-10% of participants reporting minor hypoglycemia.
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on metformin, continuing liraglutide 1.8 mg/day for 78 weeks reduced HbA1c by 1.3% from a baseline of 8.4%.

    In plain wordsIn adults with type 2 diabetes, 78 weeks of liraglutide 1.8 mg lowered HbA1c by 1.3%.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change over 78 weeks, liraglutide 1.8 mg
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 78 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −1.3%
    liraglutide 1.8 mg/day, 78 weeks

    Source sentences

    Summary
    Continuing liraglutide treatment at 1.2 mg/day and 1.8 mg/day for 78 weeks reduced HbA(1c) (baseline 8.3 and 8.4%, respectively) by -0.9 and -1.3%, respectively; FPG by -1.3 and -1.7 mmol/L, respectively; and weight by -2.6 and -3.1 kg, respectively, with 9-10% of participants reporting minor hypoglycemia.
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, continuing liraglutide 1.2 mg/day for 78 weeks reduced fasting plasma glucose by 1.3 mmol/L.

    In plain wordsIn adults with type 2 diabetes, 78 weeks of liraglutide 1.2 mg lowered fasting blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose change over 78 weeks, liraglutide 1.2 mg
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg/day · 78 weeksAs given in this study (human).

    Measurements

    FPG change
    −1.3 mmol/L
    liraglutide 1.2 mg/day, 78 weeks

    Source sentences

    Summary
    Continuing liraglutide treatment at 1.2 mg/day and 1.8 mg/day for 78 weeks reduced HbA(1c) (baseline 8.3 and 8.4%, respectively) by -0.9 and -1.3%, respectively; FPG by -1.3 and -1.7 mmol/L, respectively; and weight by -2.6 and -3.1 kg, respectively, with 9-10% of participants reporting minor hypoglycemia.
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, continuing liraglutide 1.8 mg/day for 78 weeks reduced fasting plasma glucose by 1.7 mmol/L.

    In plain wordsIn adults with type 2 diabetes, 78 weeks of liraglutide 1.8 mg lowered fasting blood sugar.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose change over 78 weeks, liraglutide 1.8 mg
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 78 weeksAs given in this study (human).

    Measurements

    FPG change
    −1.7 mmol/L
    liraglutide 1.8 mg/day, 78 weeks

    Source sentences

    Summary
    Continuing liraglutide treatment at 1.2 mg/day and 1.8 mg/day for 78 weeks reduced HbA(1c) (baseline 8.3 and 8.4%, respectively) by -0.9 and -1.3%, respectively; FPG by -1.3 and -1.7 mmol/L, respectively; and weight by -2.6 and -3.1 kg, respectively, with 9-10% of participants reporting minor hypoglycemia.
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  15. 15HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, continuing liraglutide 1.2 mg/day for 78 weeks reduced weight by 2.6 kg.

    In plain wordsIn adults with type 2 diabetes, 78 weeks of liraglutide 1.2 mg lowered body weight by about 2.6 kg.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change over 78 weeks, liraglutide 1.2 mg
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 mg/day · 78 weeksAs given in this study (human).

    Measurements

    Weight change
    −2.6 kg
    liraglutide 1.2 mg/day, 78 weeks

    Source sentences

    Summary
    Continuing liraglutide treatment at 1.2 mg/day and 1.8 mg/day for 78 weeks reduced HbA(1c) (baseline 8.3 and 8.4%, respectively) by -0.9 and -1.3%, respectively; FPG by -1.3 and -1.7 mmol/L, respectively; and weight by -2.6 and -3.1 kg, respectively, with 9-10% of participants reporting minor hypoglycemia.
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  16. 16HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, continuing liraglutide 1.8 mg/day for 78 weeks reduced weight by 3.1 kg.

    In plain wordsIn adults with type 2 diabetes, 78 weeks of liraglutide 1.8 mg lowered body weight by about 3.1 kg.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change over 78 weeks, liraglutide 1.8 mg
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/day · 78 weeksAs given in this study (human).

    Measurements

    Weight change
    −3.1 kg
    liraglutide 1.8 mg/day, 78 weeks

    Source sentences

    Summary
    Continuing liraglutide treatment at 1.2 mg/day and 1.8 mg/day for 78 weeks reduced HbA(1c) (baseline 8.3 and 8.4%, respectively) by -0.9 and -1.3%, respectively; FPG by -1.3 and -1.7 mmol/L, respectively; and weight by -2.6 and -3.1 kg, respectively, with 9-10% of participants reporting minor hypoglycemia.
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.
  17. 17HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, 9-10% of participants continuing liraglutide for 78 weeks reported minor hypoglycemia.

    In plain wordsIn adults with type 2 diabetes, 9-10% of people taking liraglutide for 78 weeks had mild low blood sugar.

    Peptide
    Liraglutide
    Outcome
    Not applicableMinor hypoglycemia over 78 weeks of continued liraglutide
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.2 or 1.8 mg/day · 78 weeksAs given in this study (human).

    Measurements

    Minor hypoglycemia incidence
    9 to 10%
    78 weeks

    Source sentences

    Summary
    with 9-10% of participants reporting minor hypoglycemia.
    2 context sentences
    Summary · context
    In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each added to metformin, continued treatment for 52 weeks.
    Summary · context
    In a 26-week extension, sitagliptin-treated participants were randomly allocated to receive instead liraglutide at either 1.2 or 1.8 mg/day, while participants originally randomized to receive liraglutide continued unchanged.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 665Jun 2008 to Jun 2010

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.